Predicting outcomes in NSCLC with combined CD8 and PD-L1 biomarkersImproved OS following ICI treatment is associated with high CD8T and PD-L1 in mNSCLCINDICATIONLungBIOMARKERPDL1Related casesIL33 expression as a predictor of immunotherapy response in NSCLCImpact of B cell and CD8 T cell infiltration on immunotherapy outcomes in NSCLCImpact of VEGF expression on pembrolizumab outcomes in mNSCLC
